ASCO Breakthrough Conference | Conference

Wearable-Captured Metrics and ePROs Prove Feasible as Digital Ecosystem in Waldenström Macroglobulinemia

August 12th 2024

Wearable-captured physiological metrics and electronic patient reported outcomes were practical and generated knowledge in Waldenström macroglobulinemia.

Atezolizumab/Bevacizumab Represents Potential Therapeutic Option in Child-Pugh B7 HCC

August 12th 2024

Atezolizumab plus bevacizumab showed efficacy in patients with hepatocellular carcinoma who had Child-Pugh B7 liver function.

RPS-Optimized Checkpoint Inhibition Bolsters pCR in Patients With Select Rare Breast Cancers

August 9th 2024

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Enfortumab Vedotin/Pembrolizumab Does Not Negatively Impact QOL in Metastatic Urothelial Cancer

August 9th 2024

Enfortumab vedotin plus pembrolizumab improved survival vs chemotherapy with no QOL detriment in previously untreated metastatic urothelial cancer.

CIRT Plus Durvalumab/Tremelimumab Is Safe in Advanced HCC With Macrovascular Invasion

August 8th 2024

CIRT plus durvalumab and tremelimumab was safe in patients with advanced hepatocellular carcinoma with macrovascular invasion.

Olomorasib Plus Pembrolizumab Generates Antitumor Activity in KRAS G12C+ NSCLC

August 8th 2024

Olomorasib plus pembrolizumab demonstrated responses in first-line metastatic KRAS G12C–mutant non–small cell lung cancer.

Pacritinib Demonstrates Safety in Solid Tumors Harboring 1q21.3 Amplifications

August 8th 2024

Pacritinib was tolerable with a reasonable safety profile in patients with solid tumors harboring 1q21.3 copy number amplifications.

Selpercatinib Maintains PFS Benefit vs Chemotherapy in East Asian Patients With Untreated RET+ NSCLC

August 7th 2024

East Asian patients with RET fusion-positive NSCLC experienced a PFS benefit when treated with selpercatinib vs chemotherapy with/without pembrolizumab.

IMRT Alone is Non-Inferior to CCRT in Nasopharyngeal Carcinoma

August 6th 2024

Radiotherapy was non-inferior vs chemoradiotherapy in patients with nasopharyngeal carcinoma, and less toxicity was observed with radiotherapy alone.